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● Randomized controlled trials (RCTs) provide the best source of evidence for research 
syntheses estimating relative effects of an intervention.  
● Non-randomized studies of representative populations can provide the best evidence 
with respect to prognosis, baseline risk, test accuracy, and estimates of utility and values 
and preferences of different outcomes. 
● For many research questions randomized trials will be scarce or unavailable, and 
decision-makers might need to consider using non-randomized (observational) studies 
that can provide evidence about the effectiveness of interventions as replacement (in the 
absence of appropriate RCT evidence), sequential, or complementary to RCT evidence 
● GRADE guidance can help authors that are considering the inclusion of non-randomized 
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This is the 24th in the ongoing series of articles describing the GRADE approach for 
assessing the certainty of a body of evidence in systematic reviews and health technology 
assessments and how to move from evidence to recommendations in guidelines. 
Guideline developers and authors of systematic reviews and other evidence syntheses 
use randomized controlled studies (RCTs) and non-randomized studies of interventions 
(NRSI) as sources of evidence for questions about health interventions. RCTs with low 
risk of bias are the most trustworthy source of evidence for estimating relative effects of 
interventions because of protection against confounding and other biases. However, in 
several instances, NRSI can still provide valuable information as complementary, 
sequential, or replacement evidence for RCTs. In this article we offer guidance on the 
decision regarding when to search for and include either or both types of studies in 
systematic reviews to inform health recommendations. This work aims to help 
methodologists in review teams, technology assessors, guideline panelists, and anyone 
conducting evidence syntheses using GRADE. 
 
Keywords: GRADE, quality of evidence, certainty of evidence, risk of bias, non-
randomized studies, ROBINS. 
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What is new? 
Key findings 
 GRADE provides guidance for deciding when to use different types of individual 
studies to be included in evidence synthesis of health interventions, whether 
authors consider RCTs or NRSI. 
What this adds to what is known? 
 Using a framework that considers the certainty of evidence of randomized and 
non-randomized studies, first separately and then in an integrative fashion, can 
help with the decision to include one or both types of studies in evidence 
syntheses. 
What is the implication, what should change now? 
 This GRADE guidance will help increase the certainty and comprehensiveness of 
a body of evidence to answer a question about a health intervention and improve 
recommendations by considering different types of study designs. 
  




Randomized controlled trials (RCTs) provide the best source of evidence for research 
syntheses estimating relative effects* of an intervention that might inform health 
guidelines. Non-randomized studies of representative populations can provide the best 
evidence with respect to prognosis, baseline risk, test accuracy, and estimates of utility 
and values and preferences of different outcomes.[1-3] Non-randomized studies may 
also provide evidence about the effectiveness of interventions as replacement (in the 
absence of appropriate RCT evidence), sequential, or complementary to RCT evidence 
(see box 1).[4] While non-randomized studies of interventions (NRSI) may potentially 
provide more generalizable or precise evidence compared to RCTs, confounding and 
other biases restrict their use.[5]  
 
Box 1. Potential role of NRSI in evidence syntheses  
Complementary — NRSI provide additional information on: 
 whether or not an intervention works in different populations that one wants to 
extrapolate to (e.g., NRSI studies provide evidence for populations not included 
in RCTs).  
 possible effect modification (e.g., NRSI provide complementary evidence that 
lend support to evidence from RCTs that suggests or refutes effect 
modification) 
 estimates of baseline risk in different non-trial settings 
Sequential — NRSI provide information that is not (yet) obtained or available from 
RCTs on: 
 long-term or rare (beneficial and/or harm) outcomes 
 correlation between surrogate outcomes and patient important outcomes 
Replacement — NRSI are used instead of RCT evidence for decision making 
because: 
 NRSI provide higher certainty evidence than RCTs (this applies when NRSI 
provide more direct and/or precise evidence that leaves us with greater overall 
confidence in estimates of effect or certainty of evidence). 
 RCTs are absent and NRSI provide the best available evidence  
 
                                                 
* We will use the term “estimates of relative effects”. The reader can assume we are referring to estimates of relative effect of 
interventions on binary outcomes or absolute effect from studies using continuous variables. 
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Authors of evidence syntheses of health interventions aim for the highest certainty 
evidence, and guideline developers need these syntheses to generate trustworthy 
recommendations. This explains the advisability of incorporating evidence from NRSI in 
systematic reviews when they provide complementary, sequential, or replacement 
evidence to RCTs.[6, 7]  
If RCTs alone may be unable to answer a PICO question (population, intervention, 
comparison, and outcome) an evidence review team faces the following issues: (a) When 
to search and include both types of study designs? (b) What are the optimal methods to 
synthesize information from both type of studies, including the decisions about pooling 
data from different study designs? (c) How should authors present results in evidence 
profiles and summary of findings tables? and (d) When both RCTs and NRSI contribute 
to the evidence synthesis, what is the possible influence on certainty of the evidence? 
Interpretation issues may be particularly challenging when RCTs and NRSI show 
differences in the direction or magnitude of effects, as well as in other individual 
GRADE domains. This 24th article in the ongoing GRADE series in the Journal of 
Clinical Epidemiology represents the GRADE Working Group guidance assessing the 
first question: that is, when is it appropriate to search for and include NRSI in addition 
to RCTs during the evidence synthesis process. 
2. Methods and outline 
This guidance is based on previous published work [4, 6, 8], scoping reviews, and 
surveys of experts and members of Cochrane and the Guidelines International Network 
(GIN). We used an iterative approach to develop and refine the concepts addressed in 
this guidance during face-to-face and online meetings with members of the GRADE Risk 
of Bias in Non-randomized Studies Risk of Bias Project Group specifically, and the 
GRADE Working group more broadly. In the first section, we will consider reasons for 
integrating NRSI at the early stages of formulating a research question for an evidence 
synthesis. The second section presents possible scenarios encountered when evaluating 
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a body of evidence (for a given outcome) that includes RCTs and NRSI. Finally, we 
discuss future areas of research. 
For this guidance, we define evidence synthesis as any systematic review, rapid 
review, health technology assessment or any other method aiming to summarize the 
evidence with the highest certainty available for a specific question about the effects of 
an intervention.[9] We address the perspectives of both evidence synthesis authors and 
guideline developers — who aim to produce recommendations. Although we will at 
times mention that NRSI are ideal for assessing baseline risk, our focus is primarily on 
the use of NRSI to estimate relative effects of health interventions and technologies 
(e.g., medications, behavioral interventions, devices). Lastly, when we use the term 
―integration‖ it will broadly refer to any form of using RCT and NRSI together, either in 
the same synthesis, or in the same summary of findings (same table but separated in 
rows). 
3. When to include and search for non-randomized studies in 
evidence syntheses of interventions? 
3.1. The role of a protocol and search strategy 
Figure 1 depicts a flowchart of the proposed steps to incorporate RCTs and NRSI in an 
evidence synthesis. It is important for authors to detail from the outset (i.e., at the 
protocol stage [at Point #1 in Figure 1]) any pre-specified criteria about the design of the 
studies they will search for (RCT, NRSI, or both) and the circumstances in which they 
will include these studies. 
Guideline developers and authors of systematic reviews may have reasons to search for 
and include NRSI from the outset — this is, other than for assessing relative effects of 
interventions — irrespective of the availability of RCTs (Point #2 in Figure 1). For 
instance, a common reason would be to address baseline risks, or to assess interventions 
and outcomes for which RCTs are unfeasible, unethical to conduct, sparse or unavailable 
(e.g., rare adverse outcomes or in emergent conditions), or when authors anticipate very 
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serious indirectness in the evidence from RCT. This guidance will focus on the common 
situation when review authors have reasons to believe that NRSI will provide 
complementary, sequential, or replacement information that will make important 
contributions to the overall certainty of evidence. 
The review team, before finalising the protocol (depicted in Figure 1 as the shaded area), 
must scope the available evidence and specify the criteria for the best study designs for 
different research (PICO) questions [10]. The scoping review, as precursor of the 
systematic review during the protocol stage, allows authors to detect and describe 
appropriate synthesis methods, analyze the gaps in the knowledge base, and facilitate 
estimating the amount of work and resources needed to complete the review [11, 12]. 
The specific type of NRSI to be included should not rely on classic 'evidence hierarchies' 
for studies of effectiveness, but rather on an assessment of the individual PICO question 
and the eligibility criteria; this is, the best NRSI design that is likely to be available and 
provide the highest certainty of evidence.[13] 
The scoping review will inform the reviewers if RCTs are likely to be available, or if there 
is some uncertainty around the issue (Point #3 in Figure 1); this decision, once is 
resolved, should be established in the protocol, as well as any other inclusion criteria. 
Once the protocol is accepted, the following step is a full, sensitive literature search with 
screening of titles and abstracts that will include both types of studies (RCTs and NRSI) 
for the research question (point #4, Figure 1). In most situations, the search strategy 
from the scoping review will be comprehensive enough to be used for the full systematic 
review, and a single search strategy will be sufficient. 
The references obtained from the literature search can be sorted by study design (first 
RCTs, then NRSI). Current reference managers and filters can make this sorting process 
feasible. [14, 15] At this stage (point #4 in Figure 1), authors can, after screening titles 
and abstracts, separate RCTs from NRSI; if RCTs are found, reviewers may proceed to 
extract data and assess the risk of bias and GRADE the certainty of the evidence (points 
#4 and #5 from Figure 1). However, if RCTs are not available, reviewers will proceed to 
evaluate the NRSI found from the search strategy. 
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This process requires a review team with the appropriate content and methodological 
expertise, with a protocol describing precise methods for the optimal use of RCTs and 
NRSI. Although screening and reviewing NRSI are more time consuming than for RCTs 
[11], a strategy that includes and sorts all likely study designs is efficient to attain the 
most comprehensive and appropriate body of evidence. We stress the requirement to 
have an information specialist in the team with expertise in systematic reviews and 
scoping reviews. [16, 17] At this point, experts and the review team may be certain that 
there is either sufficient RCT evidence to address relative effects for all important 
outcomes or, alternatively, that there is no RCT evidence for one or more patient-
important outcomes and should move to only use NRSI. 
3.2. When to include non-randomized studies 
After completing the sorting process and data extraction and risk of bias evaluation of 
available RCTs, authors should use the GRADE methodology to assess each RCT. 
Importantly, this assessment should always be made considering each outcome to rate 
the certainty of the body of evidence (points #5 and #6 of Figure 1). If authors conclude 
there is high certainty of evidence from RCTs, further evaluation of NRSI to 
complement estimates of relative effect for that outcome will not be necessary and 
authors can use only the evidence from RCTs. We emphasise that high certainty 
evidence for some important outcomes (typically benefit) provides no guarantee of high 
certainty evidence for other important outcomes (typically rare harms)[10, 11] and for 
this reason this process should always be considered for each outcome separately. 
We have identified two general scenarios when there is no high certainty evidence from 
RCTs (within Point #6, Figure 1): First, in situations where RCT evidence is deemed low, 
or very low certainty, NRSI may help increase the overall level of certainty. Reviewers 
should search for and evaluate NRSI, if they consider it plausible that NRSI will yield 
evidence equal or superior to that from the RCTs. In table 1 we present an example to 
visualize NRSI evidence of equal certainty than RCT evidence for an outcome. In this 
case, similar evidence classified as the same certainty could be useful for decision-
making. Second, when certainty of evidence from RCTs is rated moderate, authors 
should consider integrating NRSI evidence if it could mitigate concerns about 
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indirectness in the RCT evidence. This situation will be more likely to occur when 
indirectness is present and NRSI evidence serves as complementary or sequential 
evidence. In this scenario, it will be unlikely to find NRSI categorized as high or 
moderate certainty that trumps the RCTs, because NRSI can only be correctly classified 
as such when authors find reasons for rating up (typically–very–large effects or dose 
response relationships), or (on rare occasions) when assessed as low risk of bias — using 
an appropriate risk of bias tool, such as ROBINS-I (see below). Large NRSI with precise 
effect estimates that narrow confidence intervals may be tempting to use; however, 
caution should be used as they can be misleading if their estimates are biased. 
Once it has been decided to use NRSI based on any of the above situations, authors 
should go back to screen and evaluate the group of references of NRSI that were 
available from the scoping of the literature (Points #7 and #8, Figure 1) as these may 
complement, replace, or used in sequence (as explained in Box 1). This would be based 
on the initial criteria for NRSI established in the protocol (Points #8 and #9, Figure 1). 
4. Integrating randomized and non-randomized studies in 
evidence syntheses 
4.1. Possible scenarios when dealing with two bodies of evidence 
In figure 2 we present the possible scenarios that can arise when bodies of evidence of 
RCTs and NRSI may answer the same health question for a specific outcome. Although 
16 combinations are theoretically possible, looking for NRSI is not necessary in some 
situations; for instance, for cells A, B, C, and D, the evidence from RCTs already 
provides high certainty and perfectly answers the question, including with regards to 
applicability, hence looking for NRSI will be unnecessary because the high certainty will 
not be improved. Other scenarios (for example, cells E, I, M) are highly unlikely to occur 
for benefits (although they are plausible for adverse outcomes when large effects in 
RCTs are imprecise) and looking for NRSI may rarely be informative in these situations 
or will require individual case assessment of the reasons for lower certainty in RCTs. In 
other cases (cells F, G, H, J, K, L of figure 2) looking for NRSI may be informative, but 
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individual case assessments of reasons for lower certainty in RCTs are required — for 
example, indirectness in RCTs can be mitigated by NRSI. When RCTs provide very low 
certainty in the evidence, looking for NRSI may be useful as in cells M, N, O, P (although 
situations M and N are less likely to occur, and for P, evidence from NRSI would not 
increase the certainty). 
4.2. Future guidance for using randomized and non-randomized studies in 
systematic reviews and health guidelines 
In systematic reviews that include RCTs and NRSI, evidence from both type of studies 
can be presented either separately as narrative syntheses (with tables summarizing the 
evidence from RCT and NRSI), as quantitative analyses (in separate meta-analyses or a 
single pooled estimate), or a combination of both. In a recent survey we asked authors of 
systematic reviews about their preferences when facing a research question that could 
be informed by RCTs and NRSI; 17.5% preferred combining RCTs and NRSI into a 
single pooled estimate (i.e., in meta-analyses), while a majority reported their findings 
separately for the two types of study designs — either in sub-groups, in separate meta-
analyses, or in narrative tables.[6] The issue of integration (using the two types of 
evidence in any of these forms) and the options for portraying both types of study will be 
discussed in depth in subsequent GRADE guidance. 
When crafting health recommendations, guideline development groups or panelists 
must decide if using the two bodies of evidence would leave them with higher certainty 
in the evidence than if they would use only one of the bodies of evidence, considering 
each GRADE domain affected and the implications on the final recommendation per 
outcome. 
5. The role of ROBINS-I 
Until now, we have assessed the integration of both bodies of evidence in GRADE 
irrespective of which risk of bias assessment tool had been used. Several tools to assess 
risk of bias in NRSI exist (e.g., Newcastle-Ottawa, EPIQ, CASP, ROBINS-I) [18-20] and 
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GRADE does not require the use of a specific instrument as long as the instrument is 
suitable for the purpose and the assessment of risk of bias transparent. Among these, 
ROBINS-I [5, 6] (Figure 3) represents a leeway to understand the similarities between 
RCTs and NRSI more than their differences. We previously described the impact of 
using ROBINS-I in GRADE in detail.[6] 
A useful contribution of the ROBINS-I tool, within the framework of developing a 
systematic review, is the conceptualization and consideration of a ―target trial‖ (i.e., a 
hypothetical, large, pragmatic RCT that assesses the effect of the same intervention in 
the same population), which prompts authors assessing a clinical question about an 
intervention to ask, how a study that answers this question would be conducted by a 
randomized controlled experiment, regardless of the feasibility to do it. The target trial, 
in terms of the integration of NRSI with RCTs, facilitates the comparison between RCT 
and NRSI because they are placed on a common metric allowing the investigator to 
evaluate bias in the NRSI compared to the target trial.  
The main difference between RCTs and NRSI results from randomization that protects 
essentially against imbalances in prognostic factors.[6] In ROBINS-I, a low risk of bias 
NRSI would be considered equal to a well conducted RCT. If the assumption that NRSI 
have none or minimal concerns of bias due to confounding and selection of participants 
holds — for example, in an (ideally) well conducted interrupted time series — there 
should be no major concerns when such NRSI are integrated with RCT, especially if 
other GRADE domains are similar and effect estimates are coherent. However, we have 
not yet identified an example in which this is the case. Studies assessed with ROBINS-I 
may also yield high certainty evidence if other classical upgrading domains apply (e.g., if 
very large effects are present).[6] This and other issues are still debated and will be 
discussed and presented in future GRADE guidance. 
6. Summary and next steps 
Including both RCTs and NRSI in a single systematic review or health guideline has 
generated controversy and diverse opinions.[21] GRADE can guide authors of evidence 
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syntheses in considering RCTs and NRSI to inform health questions. In some situations, 
review teams will decide not to search for NRSI to address issues of relative effects, for 
instance, when they anticipate identifying large well-conducted RCTs evaluating the 
efficacy of an intervention. Under such circumstances, searching, screening, analyzing, 
and presenting evidence from NRSI will unnecessarily add substantial work. Yet, on 
occasions it may be desirable to search other sorts of NRSI that can inform specific 
issues such as baseline risks for an outcome in people not receiving an intervention. 
Practitioners, coverage decision makers, health policymakers, and other stakeholders 
often face challenging health questions for their decisions and recommendations. These 
questions require evidence syntheses that strive for the highest certainty of evidence, 
whether this comes from high certainty RCTs or from NRSI that further complement 
(e.g. when indirect or imprecise) or replace the body of evidence from RCTs (if the 
evidence from NRSI is of higher overall certainty than RCTs).  
In this article, we provide guidance for authors interested in maximizing the amount of 
informative evidence in health syntheses from different study designs. In subsequent 
work, we will address the issue of using both RCTs and NRSI in systematic reviews 
using GRADE, including the question of whether or not to pool them, and if they can be 
pooled, what conditions should be fulfilled. Meanwhile, further research is needed to 
address the distribution of GRADE certainty of evidence levels in systematic reviews 
that includes RCTs and NRSI, or which GRADE domains prove to have serious 
limitations when review authors consider both bodies of evidence.  
7. Summary points 
 The GRADE approach supports authors in deciding whether to search for and 
integrate NRSI with RCT in evidence syntheses about health interventions. 
 If authors identify RCTs that prove to have high certainty evidence for critical 
and important outcomes, we suggest not screening, nor using NRSI for an 
evidence synthesis. 
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 With moderate certainty of evidence from RCTs, it is unlikely that NRSI will 
supply higher certainty than moderate. NRSI will be classified as high or 
moderate only when authors can show reasons for rating up (typically –very– 
large effects, dose response relationships or opposing plausible residual 
confounding). However, NRSI may serve as complementary or sequential 
evidence when the reason to downgrade RCTs to moderate is due to indirectness. 
 When authors anticipate or identify low certainty evidence from RCTs for critical 
or important outcomes, in particular undesirable health outcomes, searching for 
relevant NRSI may allow drawing conclusions with more confidence if they have 
information suggesting well-done NRSI are available (i.e., NRSI that may 
complement or be used in sequence to RCTs)  
 When authors anticipate or identify very low certainty evidence from RCTs for 
critical or important outcomes, in particular undesirable health outcomes, they 
should also search for relevant NRSI (i.e., NRSI may complement, replace, or be 
used in sequence to RCTs) 
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Flowchart depicting the process of conducting a systematic review about a health 
intervention considering the role of randomized and non-randomized studies. The 
explanations are portrayed as dark grey circles. See text for detailed description of each 
step. The grey area represents the steps that might be taken during the protocol 
development. Of note, as stated in the GRADE guidance, the assessment of the certainty 
of evidence should be made for each outcome evaluated in the review process. 
*In most situations, the search strategy performed for the scoping review will be 
comprehensive enough to be used at this step; however, authors may prefer to run 
another search or include changes from the one in the scoping review. 
Figure 2 
Situations after assessment of the GRADE certainty of evidence when NRSI and RCTs 
are included in an evidence synthesis. See also Point 9 from Figure 1 and full description 
within the text. 
Figure 3 
Types of bias met in non-randomized studies (left column) based on the ROBINS-I tool 
and randomized studies (right column) based on the RoB 2.0 tool, with the situations or 
actions that, when properly performed (center column), protects against these biases in 
RCTs and would prevent bias in NRSI if we were able to do a random assignment of 
participants; this is the hallmark feature of the ‗target trial‘. To the right, in parentheses, 
are depicted other nomenclatures for biases, which are based on the classic (previous) 
risk of bias tool from Cochrane. 
  
         
 
 22 
TABLE 1. Evidence profile using randomized and non-randomized studies of 




































































































































Question: Vitamin D compared to no vitamin D in pregnant women for preventing asthma or wheezing in their 
offspring  
Setting: ambulatory 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio 
Explanations 
a. There were 22/180 participants who were not analyzed (lost to follow-up), 16% in the intervention group and 10% 
in the control group. Also, the outcome was a subjective measure and participants were not blinded to treatment 
allocation (reporter bias).  
b. Wide confidence interval with a small number of participants for the optimal information size; also, crossing the null 
and the appreciable thresholds for benefit and harm.  
c. All studies have bias due to possible residual confounding and bias due to selection of participants. The non-
randomized studies thus are downgraded two levels. The ROBINS-I tool was used. No further downgrading was 
considered necessary.  
d. All individual studies report a significant dose-response association at various levels of vitamin D supplementation 
on the risk of asthma or wheezing. This, however, can be due to a spurious effect if residual confounding remains 
within each study. By visually inspecting the forest plot based on different vitamin D dosages, the effect looks 
minimal. We decided not to upgrade but if such case were considered, the overall certainty will end as MODERATE.  
e. All studies provide the adjusted odds ratios on the risk of asthma and its association with vitamin D intake. 
Baseline risk in the control group was assigned from the rest of the studies, including the randomized controlled trial.  
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